Response to "Dose Rationale for Favipiravir Use in Patients Infected With SARS-CoV-2"
Clin Pharmacol Ther
.
2020 Aug;108(2):190.
doi: 10.1002/cpt.1878.
Epub 2020 May 21.
Authors
Yin-Xiao Du
1
2
3
,
Xiao-Ping Chen
1
2
3
Affiliations
1
Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
2
Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha, Hunan, China.
3
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China.
PMID:
32353191
PMCID:
PMC7267349
DOI:
10.1002/cpt.1878
No abstract available
Publication types
Letter
Comment
MeSH terms
Amides
Betacoronavirus*
COVID-19
Coronavirus Infections*
Humans
Pandemics*
Pneumonia, Viral*
Pyrazines
SARS-CoV-2
Severe acute respiratory syndrome-related coronavirus*
Substances
Amides
Pyrazines
favipiravir